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Introduction
Spinal muscular atrophy (SMA) is a genetic disor-
der leading to degeneration of lower motor neu-
rons, and, consequently, to severe and progressive 
muscle atrophy. SMA is not associated with cog-
nitive impairment.1 The disease is classified into 
four phenotypes, defined by the age at onset and 
the highest attained developmental motor mile-
stone (SMA I: never achieve unassisted sitting; 
SMA II: unassisted sitting; SMA III: unassisted 
walking; SMA IV: adult onset).2
Until recently, treatment of patients with SMA was 
restricted to symptomatic approaches. In 2016, 
Nusinersen was approved as the first specific ther-
apy for 5q-associated SMA in the United States, 
followed by the European Union in 2017. The 
effective molecule is an antisense oligonucleotide, 
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Abstract
Background: The antisense oligonucleotide Nusinersen recently became the first approved 
drug against spinal muscular atrophy (SMA). It was approved for all ages, albeit the clinical 
trials were conducted exclusively on children. Hence, clinical data on adults being treated 
with Nusinersen is scarce. In this case series, we report on drug application, organizational 
demands, and preliminary effects during the first 10 months of treatment with Nusinersen in 
seven adult patients.
Methods: All patients received intrathecal injections with Nusinersen. In cases with severe 
spinal deformities, we performed computed tomography (CT)-guided applications. We 
conducted a total of 40 administrations of Nusinersen. We evaluated the patients with motor, 
pulmonary, and laboratory assessments, and tracked patient-reported outcome.
Results: Intrathecal administration of Nusinersen was successful in most patients, even 
though access to the lumbar intrathecal space in adults with SMA is often challenging. No 
severe adverse events occurred. Six of the seven patients reported stabilization of motor 
function or reduction in symptom severity. The changes in the assessed scores did not reach a 
significant level within this short time period.
Conclusions: Treating adult SMA patients with Nusinersen is feasible and most patients 
consider it beneficial. It demands a complex organizational and interdisciplinary effort. Due 
to the slowly decreasing motor functions in adult SMA patients, long observation phases 
for this recently approved treatment are needed to allow conclusions about effectiveness of 
Nusinersen in adults.
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which must be administered intrathecally every 
4 months after loading (Figure 1). It has been 
approved for pediatric and adult patients, albeit the 
pivotal studies were conducted only with chil-
dren.3,4 In the pivotal studies, children with severe 
scoliosis, or very limited motor function, were 
excluded. Adult SMA patients, however, often suf-
fer from both of these conditions, which leads to 
complex challenges in clinical approach.
Data of adults being treated with Nusinersen is 
scarce.5 Thus far, Stolte and colleagues and 
Wurster and colleagues described the feasibility 
and safety of lumbar puncture for the application 
of Nusinersen in adult patients with SMA.6,7 
Walter and colleagues recently reported the treat-
ment effects in a first adult SMA type III cohort.8 
Apart from that cohort, no follow-up data describ-
ing the clinical course of adult patients receiving 
treatment with Nusinersen has been published to 
date, and no reports on adult SMA type II patients 
exist so far. Here, we report on the first 10 months 
of treatment of seven adults with SMA type II 
and III, with focus on drug application, organiza-
tional demands, patient characteristics, and pre-
liminary effects.
Methods
Seven patients aged 20–68 years were treated with 
Nusinersen for at least 10 months. We initially 
evaluated the patients in the neurologic day clinic 
including thorough patient information and treat-
ment planning. Treatment planning comprised, 
for example, a spine CT, pulmonary function 
assessment, and a request of full cost coverage by 
the health insurance company to avoid later can-
cellation of hospital costs. Subsequently, the 
patients were admitted to the Department of 
Neurology at Jena University Hospital for each 
application.
Treatment of our adult patients was conducted by 
a multidisciplinary team, comparable to the 
description by Sansone and colleagues for the treat-
ment of children.9 Our team includes neurologists 
(preparational evaluation, definition of individual 
therapeutic goals, organization and documentation 
of the treatment, and intrathecal application of 
Nusinersen in patients without major spinal 
deformities), neuroradiologists (fluoroscopic and 
CT-guided intrathecal application), and physical 
therapists (physiotherapeutic assessments).
All participants provided written informed con-
sent for publication of the data in an international 
medical journal. Confirmation was obtained from 
the ethics committee of Jena University Hospital, 
Jena, Germany, that this case series does not 
require ethical approval.
Drug administration
We applied Nusinersen intrathecally lumbar, fol-
lowing the prescribing information. In three 
patients with SMA type III who were able to sit 
unassisted or with assistance of one person, lum-
bar puncture was conducted on the ward in a sit-
ting position without local anesthetic or sedation. 
In the remaining four patients, CT-guided lum-
bar punctures were performed in a lateral position 
by experienced neuroradiologists with assistance 
by neurologists with constant cardiopulmonary 
monitoring. Three of these four patients were 
injected by transforaminal access.10 In one 
patient, we switched from fluoroscopic guidance 
to CT-guided transforaminal applications due to 
lack of cerebrospinal fluid backflow at the fourth 
injection. Severely affected patients were brought 
in position with the help of personal assistants or 
family members in order to make them as com-
fortable as possible. If requested by the patient, a 
local anesthetic (Lidocaine) was applied.
Figure 1. Treatment and assessment schedule. We began treatment shortly after a preparational day hospital 
evaluation. Within the first 2 months of treatment, four administrations of Nusinersen take place within 
the ‘loading phase’. The treatment has to be repeated every 4 months thereafter. Intrathecal injections of 
Nusinersen were conducted by neurologists and neuroradiologists, the assessments involved neurologists, 
physical therapists, the pulmonary unit, and the laboratory for blood and urine workup.
E Jochmann, R Steinbach et al.
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In two additional patients for whom Nusinersen 
application was planned in the reported time 
period, treatment was cancelled after an unsuc-
cessful first procedure. In one of the two, 
CT-guided lumbar puncture failed due to metal 
implants and calcification, in the other, the inter-
vention was discontinued due to anxiety and pain.
Assessments
We evaluated all patients before, and at 2, 6, and 
10 months after the beginning of the treatment 
(Table 1, Figure 1). Motor function was assessed 
with the Hammersmith Functional Motor Scale 
Expanded (HFMSE),11 the Revised Upper Limb 
Module (RULM),12 and the 6-Minute Walk Test 
(6MWT).13 When scoring the RULM and the 
HFMSE, evaluators rated if the motor tests were 
limited by contractures. Within the basic assess-
ment of the RULM, they additionally docu-
mented the existence of elbow contractures. 
Evaluators were either trained directly for RULM, 
HFMSE, and 6MWT in a dedicated workshop, 
instructed by trained evaluators, or studied the 
instruction manuals. Physical functioning in 
activities of daily living was evaluated by the 
Revised Amyotrophic Lateral Sclerosis Functional 
Rating Scale (ALSFRS-R).14 Furthermore, pul-
monary function was measured and extensive 
laboratory blood and urine workup was carried 
out. To achieve comparability, and to contribute 
to a multicenter registry, our clinical evaluations 
complied with national recommendations. In 
addition, quality of life was documented using 
EUROQoL EQ-5D; Patient-Reported-Outcome 
was scored with the Measure Yourself Medical 
Outcome Profile 2 (MYMOP-D, German trans-
lation of MYMOP2).15
Results
Between August 2017 and May 2019, seven adult 
patients (42 ± 18 years) with SMA type II (n = 4) 
and III (n = 3) were treated with Nusinersen in 
our hospital. For the reported treatment period of 
10 months, six of the patients received the entire 
six doses of Nusinersen. These six patients 
reported regaining of motor functions, apprecia-
ble in their daily life (for details see Table 1). 
Patient 4 was not able to receive the fifth and con-
secutive applications of Nusinersen due to the 
development of a sacral pressure ulcer close to the 
injection site. This patient reported decreasing 
strength but less dysphagia at 6 months and 
decided to discontinue the treatment with 
Nusinersen. In a routine follow up at 12 months 
after initiation of Nusinersen, we conducted the 
ALSFRS-R, which decreased by 1 point due to 
the percutaneous endoscopic gastrostomy he had 
received meanwhile.
Drug administration
Intrathecal administration of Nusinersen was fea-
sible in seven out of nine patients in the reported 
time period (78%).
A total of 18 conventional interlaminar lumbar 
punctures were performed on the ward. Overall, 
lumbar punctures in these patients did not require 
more attempts than in healthy individuals.
A total of 19 CT-guided applications were per-
formed, 15 with a transforaminal approach. 
Cardiopulmonary monitoring documented stable 
heart activity and oxygen saturation throughout 
the procedures with no need for respiratory 
support.
Three lumbar punctures with fluoroscopic guid-
ance were successful. Fluoroscopic guidance was 
arduous in presence of severe spinal deformities, 
postoperative alterations, and demineralization.
Adverse events
No severe adverse events were observed after 40 
applications of Nusinersen. The rate and nature 
of adverse events (headache after lumbar punc-
ture in two patients, proteinuria in one patient) 
are in accordance with the literature.6,7,10
Assessments
The ALSFRS-R, pulmonary assessments, EQ-5D 
index, and laboratory assessments showed no 
clinically meaningful changes for any of the seven 
patients.
In contrast, the RULM, designed to score motor 
function of the upper limb (range 0–37), depicted 
clinically meaningful improvements in three 
patients as soon as 2 months after starting the 
treatment (Figure 2, top). Their scores increased 
from baseline to 10 months of treatment by an 
average of +15.7 points (SD 4.5); the mean 
change for all six patients receiving six doses of 
Nusinersen was +7.7 (SD 9.3). The HFMSE, 
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used for the assessment of overall physical abili-
ties in SMA type II and III, showed an increase in 
the same three patients after 10 months, with an 
average of +9.3 points (SD 6.7) (Figure 2, bot-
tom). The mean change for all six patients was 
+5 (SD 6.5). The only patient able to perform 
the 6MWT walked 275 m at baseline, 327 m at 
6 months, and 343 m at 14 months (+25%). 
MYMOP-D was performed by three patients (2, 
5, and 7) throughout the first 10 months of treat-
ment for weekly self-evaluation. In patient 2, we 
documented increasing scores by more than 
1 point in two out of four items referring to 
improvement of handwriting and general wellbe-
ing after 6 months.
All four patients with SMA type II had elbow 
 contractures. The three patients with SMA type III 
had no documented contractures. The evaluators 
considered none of the motor function tests per-
formed by any of the patients as limited by contrac-
tures beyond the limitations due to the pareses.
Three out of four SMA type II patients described 
dysphagia at baseline. These three patients 
reported a subjective decrease of dysphagia within 
the first 10 months of application of Nusinersen.
Patient 1, who showed stable results in the assess-
ments during the first 10 months of treatment 
(Figure 2, Table 1), meanwhile received 
Nusinersen for a total of 22 months (9 doses). At 
his 14-month assessment, the RULM score 
increased by 11 points as compared with baseline, 
and stayed at this level until now. HFMSE score 
increased at his 22-month assessment (8 months 
later than the RULM score) by 9 points as com-
pared with baseline.
Figure 2. Changes in RULM and HFMSE scores during the first 10 months of treatment with Nusinersen. 
Absolute values of the (top) RULM score (total range 0–37 points, higher indicates better) and the (bottom) 
HFMSE score (total range 0–66 points, higher indicates better) as well as their changes between baseline and 
10th month are depicted for each individual patient. Patients are briefly characterized in brackets: sex, age in 
years at baseline, type of SMA. RULM (top) and HFMSE (bottom) scores showed clinically meaningful changes 
in three patients (patient 5, 6, 7), with RULM score depicting an increase before HFMSE score (2 versus 
10 months after initiation of the treatment). Patient 3, who is ambulatory, already started with a RULM score 
of 37 points (maximum score) at baseline. Patient 4 discontinued treatment before the fifth application (and 
herewith 6th month assessment) of Nusinersen due to the development of a sacral pressure ulcer.
HFMSE, Hammersmith Functional Motor Scale Expanded; F, female; M, male; RULM, Revised Upper Limb Module; SMA, 
spinal muscular atrophy.
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Discussion
Defining individual treatment goals prior to initi-
ating treatment with Nusinersen was of major 
importance in our center. Due to the lack of data 
regarding the effectiveness of Nusinersen in adult 
patients, the decision to continue treatment after 
1 year will take the realization of these goals into 
account.
Most of our patients defined stabilization of their 
current clinical state as the major therapeutic 
expectation, which is consistent with observations 
elsewhere.16 They emphasized breathing and 
hand motor function.
We performed multiple assessments to monitor 
the clinical condition and quality of life of the 
patients undergoing treatment. Due to the small 
and heterogenous cohort of patients reported in 
this case series, and the short time period of docu-
mentation, no statistically substantiated state-
ments about clinical benefits can be drawn from 
the assessments. It is important to note that, 
before treatment, the patients had a progression 
of disease for, on average, 36 years since onset of 
symptoms. All patients reported that, over the 
course of the 3 years preceding the start of treat-
ment with Nusinersen, their symptoms and con-
ditions had become worse.
Six out of seven patients described subjective 
improvements in motor skills since the treat-
ment with Nusinersen, which were also acknowl-
edged by personal assistants and treating 
physical therapists (Table 1). In the six patients 
with improvements, only three had increasing 
RULM and HFMSE scores, with HFMSE 
increasing later and to a lesser degree (Figure 2). 
One other patient’s RULM (patient 3, SMA 
type III) was already at the maximum possible 
score at the start, and thus could not improve. 
His HFMSE score was close to the maximum 
possible score, and fluctuated around a high 
level from test to test with no distinct tendency 
to increase or decrease. Comparable courses of 
HFMSE in SMA type III patients with large ini-
tial HFMSE scores, and improvements in the 
6MWT, have been described by Darras and col-
leagues.17 It could be assumed that the steps to 
improve HFMSE are higher with large scores.17 
At that level, skills like squatting or jumping are 
tested, which might take a longer time of train-
ing even if motor function had improved in the 
meantime.
For the remaining two patients, the lack of 
increasing RULM (and HFMSE) scores despite 
subjective motor improvements could be 
explained by the circumstance that, over time, 
they have developed strategies to optimally 
employ their remaining motor functions. This 
leads to appreciable improvements in function 
even with marginal increase in strength. The 
coarse gradings in the assessed motor scores, 
however, do not reflect these nuances.
Interestingly, in the three patients with increasing 
scores, the RULM score had already increased at 
the first assessment, 2 months after treatment ini-
tiation, while the HFMSE did not depict similar 
results before the 10 month assessment. We see 
three possible explanations for this finding: first, 
it could be interpreted as RULM being more sen-
sitive to subtle changes in motor functions than 
HFMSE. Second, since the three patients with 
increasing scores we report on had more remain-
ing motor function in the upper than in the lower 
limbs, it could be explained by an easier and ear-
lier recovery of motor function in areas with more 
muscle strength left. Third, and more specula-
tively, changes in motor function in adults under 
treatment with Nusinersen could generally ini-
tially occur in the upper limbs due to the shorter 
distance between motor neurons and muscles 
compared with the lower limbs. Thus, RULM, 
which was designed to document upper limb 
motor function, can depict increasing scores early 
on. HFMSE, with motor tests aimed at overall 
motor activities, including many items involving 
the lower limbs (with a longer distance between 
motor neurons and muscles), could therefore 
document changes only after a longer time period.
In the patients with notable increase in the RULM 
and HFMSE scores, no clear pattern of patient 
characteristics can be deduced. They were of dif-
ferent age (22, 31, 68 years old), had different 
types of SMA (II and III), and different SMA2 
gene copy numbers (2, 3, and 4). In contrast to 
our observations, a correlation between duration 
of disease and response to treatment, as well as a 
correlation between age and response to treat-
ment, was reported in children.4 On the other 
hand, Walter and colleagues also observed a lack 
of correlation in their adult cohort.8 The adult 
cohorts described so far are too small to general-
ize; however, there is no indication thus far that 
older age or longer disease duration in adults 
impacts the treatment response negatively.
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RULM and HFMSE scores increased in three of 
the patients of our cohort within the first 
10 months of treatment. Some of the assessed 
scores increased remarkably. Individual patients 
with outstanding improvements in motor assess-
ments have also been seen by others in children 
and adults.4,8 The mean changes in RULM and 
HFMSE scores of our small heterogenous cohort 
lie within the same dimensions as data reported 
elsewhere. That is, the least-squares mean 
increase in HFMSE score after 15 months 
described in children with later-onset SMA (3.9 
points) is comparable with the mean increase of 
all patients in our cohort after 10 months (5 
points).4 Of children in the Nusinersen group in 
the latter study, 57% had an increase in HFMSE 
score after 15 months, which is also consistent 
with our data of adult patients after 10 months. 
Nevertheless, the observed individual increases in 
motor scores remain astonishingly high, as 
increases in the dimension described in children 
were not expected, even in individual patients. 
Possible explanations for the observed improve-
ments in motor scores could be placebo effect, 
the learning curve for the motor tests, and an 
increased frequency and intensity of physiother-
apy due to increased motivation after starting a 
novel therapy. Furthermore, fluctuations in moti-
vation and general condition could lead to altered 
results. On a biological level, this may indicate a 
nonfunctional recoverable state of motor neu-
rons, which warrants further in-depth analysis of 
single motor units. Overall, the data suggest dif-
ferent individual responses to treatment in adults, 
similar to what has been described in children.
SMA type II patients all develop lower extremity 
contractures to some degree, which can have 
negative impact on the performance in HFMSE 
(SMA type III patients generally develop lower 
extremity contractures only to a minimal 
degree).18 This observation in SMA type II 
patients may also be transferred to the upper 
extremity and RULM. By leading to an impaired 
range of motion, contractures could be detri-
mental for motor testing in RULM. Several 
items of the RULM require the ability to fully 
extend the elbows to achieve the highest score. 
This could limit the achievable scores in patients 
at higher strength levels with elbow contractures. 
In our cohort, all SMA type II patients had doc-
umented elbow contractures. Nevertheless, as 
our assessors considered none of the motor func-
tion tests performed by any of the patients to be 
additionally limited by contractures, there is no 
indication that their treatment benefit was 
diminished by contractures within our observa-
tional period.
An improvement in the 6MWT in ambulatory 
SMA patients receiving Nusinersen has been 
described before. In a cohort of later-onset SMA 
children, Darras and colleagues reported an aver-
age of 30 m response per year, with an approxi-
mately linear increase over the course of about 
3 years of treatment.17 Furthermore, Walter and 
colleagues described 64% of 11 adult patients 
improving their walking distance in the 6MWT 
by 31 m or more after 10 months of treatment.8 
The increased walking distance in the ambulatory 
patient of our cohort (68 m after 14 months) is 
consistent with the described findings.
In general, motor assessments that are used for 
the evaluation of treatment effects of Nusinersen 
should be sensitive enough to detect small changes 
in motor function. In contrast to the RULM, the 
HFMSE, and the 6MWT, the ALSFRS-R score 
(which is not validated for SMA) remained stable 
for all patients within our observational period. 
Our data is consistent with another report of the 
first 10 months of Nusinersen treatment in 
adults.8 This points towards a rather minor poten-
tial of the ALSFRS-R to reflect a short-term ther-
apeutic improvement in SMA patients.
A decrease or stability in dysphagia and thereby a 
decrease or stability in the risk for aspirational 
pneumonias and the need for nutritional support 
(percutaneous endoscopic gastrostomy) is a 
major therapeutic aim for most of the weaker 
SMA type II patients.16 The three patients from 
our cohort with dysphagia at baseline reported a 
subjective decrease in dysphagia within the first 
10 months of treatment with Nusinersen. To 
provide objective results considering dysphagia, 
repeated swallowing studies would be needed in 
future assessments. With Nusinersen being 
approved for adults, no data derived from a pla-
cebo-controlled trial will be available. In this sit-
uation, clinical observations, as presented in this 
case series, are the best possible data with which 
to evaluate effectiveness. Thus, an inevitable lim-
itation of the data presented is that a placebo 
effect leading to increasing scores cannot be 
excluded as the data was deduced from clinical 
data from an approved treatment and not from a 
controlled clinical trial.
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Implications for clinical care
Treatment of adult SMA patients with Nusinersen 
is feasible. Most patients consider it beneficial 
and seek to continue the treatment, despite the 
burden of undergoing the unpleasant and incon-
venient procedure. It imposes a considerable 
organizational effort, including the setup of a 
well-structured treatment plan in close coordina-
tion with the patients as well as the establishment 
of a multidisciplinary medical team.
To date, no predictors of effectiveness of treat-
ment with Nusinersen in adults exist. In our 
center, we offer treatment to all 5q SMA patients, 
irrespective of age, type of SMA, SMA2 gene 
copy number, or clinical status for 1 year initially, 
after which evaluation of effectiveness takes place, 
taking into account the individual predefined 
treatment goals, motor assessments, and patient-
reported outcome. Adult SMA patients with a 
long medical history, and often with motor condi-
tions decreasing slowly over years, will need long 
observation phases in order to allow conclusions 
about effectiveness of treatment. This is under-
lined by the data presented for patient 1, whose 
RULM and HFMSE scores did not increase until 
well over a year after treatment initiation, while 
reporting subjective improvements beforehand.
Time, and increasing numbers of treated adults 
after the, only recent, approval of this treatment, 
will show whether the currently established 
motor assessments are able to sufficiently depict 
clinical status in this group of patients, and if 
Nusinersen can stabilize, or even improve, the 
situation for adult patients to a similar degree as 
is the case for children.
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